PT2532681E - Anticorpos anti-ilt7 - Google Patents
Anticorpos anti-ilt7 Download PDFInfo
- Publication number
- PT2532681E PT2532681E PT121685861T PT12168586T PT2532681E PT 2532681 E PT2532681 E PT 2532681E PT 121685861 T PT121685861 T PT 121685861T PT 12168586 T PT12168586 T PT 12168586T PT 2532681 E PT2532681 E PT 2532681E
- Authority
- PT
- Portugal
- Prior art keywords
- ilt7 antibody
- ilt7
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005366465 | 2005-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2532681E true PT2532681E (pt) | 2014-12-23 |
Family
ID=38188642
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT121685861T PT2532681E (pt) | 2005-12-20 | 2006-12-20 | Anticorpos anti-ilt7 |
| PT68429455T PT1964852E (pt) | 2005-12-20 | 2006-12-20 | Anticorpo anti-ilt7 |
| PT14186905T PT2913343T (pt) | 2005-12-20 | 2006-12-20 | Anticorpo anti-ilt7 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT68429455T PT1964852E (pt) | 2005-12-20 | 2006-12-20 | Anticorpo anti-ilt7 |
| PT14186905T PT2913343T (pt) | 2005-12-20 | 2006-12-20 | Anticorpo anti-ilt7 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8084585B2 (enExample) |
| EP (4) | EP2532681B1 (enExample) |
| JP (2) | JP5020828B2 (enExample) |
| KR (3) | KR101585532B1 (enExample) |
| CN (5) | CN110776566B (enExample) |
| AU (1) | AU2006328470B2 (enExample) |
| BR (1) | BRPI0620141B1 (enExample) |
| CA (2) | CA2634116C (enExample) |
| CY (3) | CY1114227T1 (enExample) |
| DK (3) | DK2532681T3 (enExample) |
| ES (3) | ES2416716T3 (enExample) |
| HK (1) | HK1218126A1 (enExample) |
| HR (2) | HRP20130494T1 (enExample) |
| HU (1) | HUE039865T2 (enExample) |
| IL (1) | IL192266A (enExample) |
| LT (1) | LT2913343T (enExample) |
| ME (1) | ME02111B (enExample) |
| MX (1) | MX2008007682A (enExample) |
| NZ (3) | NZ616992A (enExample) |
| PL (3) | PL1964852T3 (enExample) |
| PT (3) | PT2532681E (enExample) |
| RS (2) | RS52860B (enExample) |
| RU (2) | RU2456298C2 (enExample) |
| SG (2) | SG170749A1 (enExample) |
| SI (3) | SI2913343T1 (enExample) |
| TR (1) | TR201816574T4 (enExample) |
| UA (1) | UA97946C2 (enExample) |
| WO (1) | WO2007072866A1 (enExample) |
| ZA (1) | ZA200805850B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2892724B1 (fr) * | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii. |
| WO2011060076A1 (en) * | 2009-11-10 | 2011-05-19 | Amgen Inc. | Anti-c-mpl antibodies |
| US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
| MY171234A (en) | 2010-02-24 | 2019-10-04 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US9096660B2 (en) | 2010-04-26 | 2015-08-04 | Abraxis Bioscience, Llc | SPARC binding antibodies and uses thereof |
| EP3318273B1 (en) | 2011-04-01 | 2019-08-21 | ImmunoGen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
| EP2828284B1 (en) | 2012-03-20 | 2019-05-08 | Biogen MA Inc. | Jcv neutralizing antibodies |
| DK2828292T3 (da) | 2012-03-20 | 2019-01-02 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
| US9845356B2 (en) | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
| HUE049693T2 (hu) | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnosztikai ASSAY-k és készletek a folåt receptor 1 kimutatåsåra |
| LT3038650T (lt) | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikƫnai ir foliatƳ receptoriaus 1 nustatymo testai |
| WO2015051159A1 (en) * | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| CN109535254B (zh) * | 2013-12-24 | 2022-06-24 | ćźæŻæł°æ„ć¶èŻæ ȘćŒäŒç€Ÿ | æäșșbdca-2æäœăć ¶çäș§æčæłăć€æ žè·é žăèĄšèŸŸèœœäœăćźżäž»ç»èćć»èŻç»ćç© |
| EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| JP6892826B2 (ja) * | 2015-03-18 | 2021-06-23 | ă·ăŒăžă§ăł ă€ăłăłăŒăăŹă€ăăă | ïŒŁïœïŒïŒæäœćăłăăźè€ćäœ |
| SI3313884T1 (sl) * | 2015-06-29 | 2021-04-30 | Immunogen, Inc. | Protitelesa proti CD123 ter njihovi konjugati in derivati |
| KR102700777B1 (ko) | 2015-09-17 | 2024-08-29 | ìŽëź€ë žì ììŽììš | í-folr1 ë©Žìì í©ìČŽë„Œ íŹíšíë ìčëŁì ìĄ°í© |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA43282A (fr) * | 2015-11-19 | 2018-09-26 | Abbvie Stemcentrx Llc | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées |
| EP3407820A4 (en) | 2016-01-26 | 2019-11-06 | Cyberdontics, Inc. | Automated dental treatment system |
| US20190031780A1 (en) * | 2016-01-27 | 2019-01-31 | Siamab Therapeutics, Inc. | Compositions and methods for targeting cancer stem cells |
| ES2903280T3 (es) * | 2016-03-01 | 2022-03-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especĂficos del receptor de poliovirus humano (RPH) |
| NZ785821A (en) * | 2016-03-10 | 2025-09-26 | Viela Bio Inc | Ilt7 binding molecules and methods of using the same |
| MA44878A (fr) | 2016-04-04 | 2019-03-13 | Bioverativ Usa Inc | Anticorps anti-facteur bb du complément et utilisations de ceux-ci |
| CA3054939A1 (en) | 2017-03-03 | 2018-09-07 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
| AU2018323955A1 (en) | 2017-08-30 | 2020-03-19 | Phanes Therapeutics, Inc. | Anti-LAG-3 antibodies and uses thereof |
| JP7369121B2 (ja) | 2017-10-11 | 2023-10-25 | ăă€ăȘăă©ăăŁăă»ăŠăŒăšăčăšă€ă»ă€ăłăłăŒăăŹă€ăăă | èŁäœæŽ»æ§ăèȘçșăăæčæł |
| US11111297B2 (en) | 2017-11-17 | 2021-09-07 | Merck Sharp & Dohme Corp. | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof |
| US11396538B2 (en) | 2017-12-20 | 2022-07-26 | Radimmune Therapeutics, Inc. | Antibodies to centrin-1, methods of making, and uses thereof |
| WO2019141092A1 (zh) * | 2018-01-18 | 2019-07-25 | ćć·ç§äŒŠćæł°çç©ć»èŻèĄä»œæéć Źćž | ælag-3æäœćć ¶çšé |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | çŸćèŸćèŠèšæéć Źćž | 掻ćcd40äčćźæ Șæé«ćć ¶çšé |
| EP3790492A4 (en) | 2018-05-10 | 2022-02-09 | Cyberdontics (USA), Inc. | AUTOMATED DENTAL DRILL |
| JP7284256B2 (ja) * | 2019-08-12 | 2023-05-30 | ăăȘăłă ăă€ăȘăăžăŻăč ăȘăăăă | ïœïœïŒă«ćŻŸăăæäœăăăłăăźäœżçš |
| JP2023505203A (ja) * | 2019-12-06 | 2023-02-08 | ăăšă© ăă€ăȘ ă€ăłăłăŒăăŹă€ăăă | ïœïœïŒç”ćăżăłăăŻèłȘăäœżçšăăæČ»çæčæł |
| AR121881A1 (es) | 2020-04-20 | 2022-07-20 | Genzyme Corp | Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos |
| CN116801810A (zh) | 2020-09-03 | 2023-09-22 | çœç»çç§(çŸćœ)ć Źćž | çšäșçéœżè§Łćç»æçcnaćæçæčæłćèŁ çœź |
| AU2022270101A1 (en) * | 2021-05-04 | 2023-10-05 | Viela Bio, Inc. | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| UY40376A (es) | 2022-07-27 | 2024-01-15 | Viela Bio Inc | Formulaciones que comprenden una proteĂna de uniĂłn al transcripto 7 similar a inmunoglobulina (ilt7) |
| CN115819604B (zh) * | 2022-09-09 | 2025-04-15 | ćŁććźéȘ柀 | æćéŸdnaæäœăæ žè·é žçæź”ăçŁç ćæćć€ćšèĄæžžçŠ»dnaçæčæł |
| CN121152801A (zh) * | 2023-03-16 | 2025-12-16 | è±èçç©ć»èŻ(æć·)æéć Źćž | é¶ćilt7çæäœćć ¶çšé |
| CN116948032B (zh) * | 2023-09-19 | 2023-12-12 | æ±æșçç©ææŻ(èć·)æéć Źćž | äșșæșcd4ćć éæäœćć ¶ć¶ć€æčæłććșçš |
| CN120098124A (zh) * | 2023-12-05 | 2025-06-06 | èć·æźäčćș·ć»èŻç§ææéć Źćž | äžç§æbdca-2æäœćć ¶ć¶ć€æčæłććșçš |
| WO2026002175A1 (zh) * | 2024-06-27 | 2026-01-02 | æ éĄćŸçčćș·çç©ç§ææéć Źćž | é¶ćilt7ćcd89çé«ç»èèĄæ„ćæäœćć ¶çšé |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA952797B (en) * | 1994-04-12 | 1996-10-07 | Res Dev Foundation | Method of treating auto-immune diseases using type one interferons |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DK1156823T3 (da) * | 1999-02-12 | 2009-01-19 | Scripps Research Inst | FremgangsmÄder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier |
| PL356836A1 (en) * | 2000-02-10 | 2004-07-12 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US6897067B2 (en) * | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
| US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
| NZ532460A (en) * | 2001-10-13 | 2005-10-28 | Asterion Ltd | Glycosylphosphatidylinositol containing polypeptides |
| NZ571508A (en) * | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
| JP4498136B2 (ja) | 2002-08-01 | 2010-07-07 | ïŒłïœïœăă€ăȘăăăŻæ ȘćŒäŒç€Ÿ | ăăŠăčă€ăłăżăŒăă§ăăłçŁç现èăźæ€ćșæčæł |
| AU2003289716A1 (en) * | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| CA2537254A1 (en) | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
-
2006
- 2006-12-20 CN CN201911002539.XA patent/CN110776566B/zh active Active
- 2006-12-20 PL PL06842945T patent/PL1964852T3/pl unknown
- 2006-12-20 CN CN202510875177.4A patent/CN120718150A/zh active Pending
- 2006-12-20 DK DK12168586.1T patent/DK2532681T3/en active
- 2006-12-20 ES ES06842945T patent/ES2416716T3/es active Active
- 2006-12-20 HR HRP20130494TT patent/HRP20130494T1/hr unknown
- 2006-12-20 RS RS20130256A patent/RS52860B/sr unknown
- 2006-12-20 SG SG201102016-1A patent/SG170749A1/en unknown
- 2006-12-20 RS RS20140678A patent/RS53752B1/sr unknown
- 2006-12-20 LT LTEP14186905.7T patent/LT2913343T/lt unknown
- 2006-12-20 CA CA2634116A patent/CA2634116C/en not_active Expired - Fee Related
- 2006-12-20 PL PL12168586T patent/PL2532681T3/pl unknown
- 2006-12-20 ES ES14186905T patent/ES2699428T3/es active Active
- 2006-12-20 AU AU2006328470A patent/AU2006328470B2/en not_active Ceased
- 2006-12-20 EP EP12168586.1A patent/EP2532681B1/en active Active
- 2006-12-20 NZ NZ616992A patent/NZ616992A/en unknown
- 2006-12-20 BR BRPI0620141-5A patent/BRPI0620141B1/pt active IP Right Grant
- 2006-12-20 NZ NZ569910A patent/NZ569910A/en not_active IP Right Cessation
- 2006-12-20 KR KR1020147004977A patent/KR101585532B1/ko active Active
- 2006-12-20 EP EP06842945.5A patent/EP1964852B1/en active Active
- 2006-12-20 PT PT121685861T patent/PT2532681E/pt unknown
- 2006-12-20 EP EP14186905.7A patent/EP2913343B1/en active Active
- 2006-12-20 ES ES12168586.1T patent/ES2526079T3/es active Active
- 2006-12-20 PL PL14186905T patent/PL2913343T3/pl unknown
- 2006-12-20 JP JP2007551124A patent/JP5020828B2/ja active Active
- 2006-12-20 NZ NZ599683A patent/NZ599683A/xx not_active IP Right Cessation
- 2006-12-20 UA UAA200809418A patent/UA97946C2/ru unknown
- 2006-12-20 PT PT68429455T patent/PT1964852E/pt unknown
- 2006-12-20 SI SI200632299T patent/SI2913343T1/sl unknown
- 2006-12-20 MX MX2008007682A patent/MX2008007682A/es active IP Right Grant
- 2006-12-20 KR KR1020087017667A patent/KR101526934B1/ko active Active
- 2006-12-20 CN CN201510296327.2A patent/CN105111311B/zh not_active Expired - Fee Related
- 2006-12-20 RU RU2008129715/10A patent/RU2456298C2/ru active
- 2006-12-20 US US12/064,957 patent/US8084585B2/en active Active
- 2006-12-20 TR TR2018/16574T patent/TR201816574T4/tr unknown
- 2006-12-20 DK DK06842945.5T patent/DK1964852T3/da active
- 2006-12-20 ME MEP-2014-157A patent/ME02111B/me unknown
- 2006-12-20 CN CN200680053131XA patent/CN101379089B/zh active Active
- 2006-12-20 SI SI200631608T patent/SI1964852T1/sl unknown
- 2006-12-20 CN CN2013102707794A patent/CN103360492A/zh active Pending
- 2006-12-20 KR KR1020157004466A patent/KR101624587B1/ko active Active
- 2006-12-20 HU HUE14186905A patent/HUE039865T2/hu unknown
- 2006-12-20 EP EP18187761.4A patent/EP3441403A1/en not_active Withdrawn
- 2006-12-20 SG SG10201602095PA patent/SG10201602095PA/en unknown
- 2006-12-20 CA CA2994756A patent/CA2994756C/en active Active
- 2006-12-20 WO PCT/JP2006/325391 patent/WO2007072866A1/ja not_active Ceased
- 2006-12-20 SI SI200631864T patent/SI2532681T1/sl unknown
- 2006-12-20 DK DK14186905.7T patent/DK2913343T3/en active
- 2006-12-20 PT PT14186905T patent/PT2913343T/pt unknown
-
2008
- 2008-06-18 IL IL192266A patent/IL192266A/en active IP Right Grant
- 2008-07-04 ZA ZA200805850A patent/ZA200805850B/xx unknown
-
2011
- 2011-11-22 US US13/302,291 patent/US8470992B2/en active Active
-
2012
- 2012-02-03 JP JP2012021947A patent/JP5420688B2/ja active Active
- 2012-03-28 RU RU2012112046/10A patent/RU2599450C2/ru active
-
2013
- 2013-06-07 US US13/912,335 patent/US20130259872A1/en not_active Abandoned
- 2013-07-02 CY CY20131100538T patent/CY1114227T1/el unknown
-
2014
- 2014-12-16 HR HRP20141226TT patent/HRP20141226T1/hr unknown
- 2014-12-17 CY CY20141101048T patent/CY1116031T1/el unknown
-
2015
- 2015-12-16 US US14/971,303 patent/US20160130343A1/en not_active Abandoned
-
2016
- 2016-05-30 HK HK16106102.4A patent/HK1218126A1/zh unknown
- 2016-10-31 US US15/339,080 patent/US20170204179A1/en not_active Abandoned
-
2018
- 2018-11-07 CY CY20181101167T patent/CY1121294T1/el unknown
-
2020
- 2020-02-24 US US16/799,441 patent/US20200339682A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL187106A (en) | Sclerostin binds antibody | |
| IL190472A0 (en) | Anti-glypican-3 antibody | |
| IL192266A0 (en) | Anti-ilt7 antibody | |
| IL185366A0 (en) | Antibody | |
| SG10201404801YA (en) | Monoclonal antibody | |
| IL181575A0 (en) | Anti-ox40l antibodies | |
| IL185380A0 (en) | ANTI-MAdCAM ANTIBODY COMPOSITIONS | |
| IL228032A0 (en) | Antibodies | |
| PL2011869T3 (pl) | Nowe przeciwciaĆo anty-CD98 | |
| ZA200709456B (en) | Anti-IL2 antibodies | |
| GB0615662D0 (en) | Antibody | |
| GB0420466D0 (en) | Anti-glucan antibodies | |
| GB0517487D0 (en) | Antibodies | |
| ZA200701952B (en) | Anti-OX40L antibodies | |
| GB0624980D0 (en) | Modification | |
| IL215528A0 (en) | Improved immunoassay methods | |
| EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
| EP1780221A4 (en) | ANTI-SYNOVIOLIN ANTIBODY | |
| GB0505489D0 (en) | Antibodies | |
| GB0418415D0 (en) | Antibody | |
| GB0505054D0 (en) | Antibodies | |
| GB0512278D0 (en) | Antibodies | |
| GB0500400D0 (en) | Antibody | |
| GB0420771D0 (en) | Antibody | |
| GB0519883D0 (en) | Antibodies |